- US-listed companies
- U.S. Stem Cell, Inc.
- Income statement
U.S. Stem Cell, Inc.【USRM】Income statement
Market cap
$64.15K
P/E ratio
| 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2020/12 | 2021/12 | 2022/12 | |
| Revenue | 1 | 1 | 1 | 2 | 2 | 3 | 6 | 7 | 277,087 | 200,749 | 82,049 |
| Revenue growth (%) | - | - | |||||||||
| Cost of revenue | 550,834 | 551,904 | 582,735 | 844,941 | 972,957 | 972,009 | 2 | 2 | 64,117 | 52,030 | 23,767 |
| Gross profit | 657,697 | 717,736 | 782,990 | - | 1 | 2 | 4 | 5 | 212,970 | 148,719 | 58,282 |
| Gross margin (%) | - | ||||||||||
| Research & development | 64 | 65 | 65 | 66,420 | 10,000 | 919 | 6,644 | 5,439 | - | - | - |
| Selling, general & administrative | 35 | 37 | 39 | 5 | 4 | 3 | 4 | 6 | 3 | 2 | 2 |
| Operating margin (%) | |||||||||||
| Operating expenses | 100 | 102 | 105 | 6 | 4 | 3 | 4 | 6 | 3 | 2 | 2 |
| Operating income | -2,665,884 | -2,534,843 | -2,831,750 | -3,529,452 | -2,605,734 | -1,159,559 | -804,681 | -1,097,903 | -2,400,241 | -2,135,858 | -1,720,484 |
| Income before tax | -4,697,037 | -4,016,467 | -3,143,259 | -2,253,511 | -1,641,880 | -2,070,386 | -3,481,491 | -2,160,427 | -2,890,493 | -3,287,416 | -2,857,943 |
| Pretax margin (%) | -388.7 | -316.3 | -230.2 | -109.6 | -74.9 | -67.1 | -63.1 | -32.2 | -1,043.2 | -1,637.6 | -3,483.2 |
| Provision for income taxes | - | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate (%) | - | - | - | - | - | - | - | - | - | - | - |
| Net income | -4,697,037 | -4,016,467 | -3,143,259 | -2,253,511 | -1,641,880 | -2,070,386 | -3,481,491 | -2,160,427 | -2,890,493 | -3,287,416 | -2,857,943 |
| Net income margin (%) | |||||||||||
| EBITDA | - | - | |||||||||
| EBITDA margin (%) | - | - |